Gossamer Bio, Inc. (GOSS) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The company operates as a single segment and relies heavily on its collaboration with Chiesi Farmaceutici S.p.A. for funding and commercialization rights outside the U.S.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $9.9 million | $0 |
| Net Loss | $(36.6) million | $(41.9) million |
| Net Loss Per Share (Basic/Diluted) | $(0.16) | $(0.19) |
| Operating Expenses | $46.7 million | $42.0 million |
| Cash, Cash Equivalents & Marketable Securities | $257.9 million | $280.5 million (Total Assets) |
| Long-Term Debt (2027 Notes) | $197.8 million (Carrying Value) | $197.5 million |
| Accumulated Deficit | $(1,305.2) million | $(1,268.6) million |
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $9.9 million in revenue in Q1 2025, compared to zero in Q1 2024. This revenue is derived entirely from the Chiesi Collaboration Agreement, specifically cost-sharing reimbursements for research and development services.
- Net Loss Improvement: Net loss decreased by $5.3 million (12.6%) year-over-year, driven by the new revenue stream and a reduction in interest expense following the termination of a previous credit facility in May 2024.
- R&D Expenses: Research and development expenses increased by $5.6 million to $38.0 million, primarily due to increased costs for the seralutinib program ($36.3 million), offset by lower costs for terminated programs.
- Liquidity: Cash and cash equivalents decreased by $17.1 million during the quarter due to operating cash outflows, though total liquid assets (including marketable securities) remain at $257.9 million.
Outlook, Risks, and Management Commentary
- Clinical Milestones: The company expects to report topline data from the registrational Phase 3 PROSERA study for PAH in February 2026. Activation of clinical sites for the Phase 3 SERANATA study for PH-ILD is expected in Q4 2025.
- Liquidity Runway: Management believes current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months from the filing date.
- Collaboration Dynamics: Under the Chiesi agreement, the company shares development costs equally with Chiesi (except for the PROSERA study, which Gossamer funds entirely) and will share U.S. commercial profits/losses equally. Chiesi holds an equity option to purchase up to 9.9% of Gossamer's outstanding stock.
- Risks: The company faces risks related to the failure of clinical trials, inability to raise additional capital, and potential changes in U.S. trade policy (tariffs) that could impact global supply chains. The company has an accumulated deficit of over $1.3 billion and expects to continue incurring losses.
Investor Verification Checklist
- Verify the timeline and enrollment status of the Phase 3 PROSERA (PAH) and SERANATA (PH-ILD) clinical trials.
- Monitor the company's cash burn rate relative to the stated 12-month liquidity runway.
- Review the terms of the Chiesi Collaboration Agreement regarding cost-sharing obligations and potential milestone payments.
- Assess the impact of the 5.00% Convertible Senior Notes due 2027 on future capital structure and potential dilution.
- Confirm the status of the equity option granted to Chiesi and any potential exercise activity.